• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

迈向70%的宫颈癌筛查覆盖率：增加人乳头瘤病毒（HPV）检测可及性的技术挑战与机遇

Toward 70% cervical cancer screening coverage: Technical challenges and opportunities to increase access to human papillomavirus (HPV) testing.

作者信息

Kundrod Kathryn A, Jeronimo Jose, Vetter Beatrice, Maza Mauricio, Murenzi Gad, Phoolcharoen Natacha, Castle Philip E

机构信息

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, United States of America.

FIND, the Global Alliance for Diagnostics, Geneva, Switzerland.

出版信息

PLOS Glob Public Health. 2023 Aug 16;3(8):e0001982. doi: 10.1371/journal.pgph.0001982. eCollection 2023.

DOI:10.1371/journal.pgph.0001982
PMID:37585432
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10431663/
Abstract

The World Health Organization (WHO) has called for the elimination of cervical cancer as a public health problem. Cervical cancer screening through human papillomavirus (HPV) testing is a core component of the strategy for elimination, with a set target of screening 70% of women twice in their lifetimes. In this review, we discuss technical barriers and opportunities to increase HPV screening globally.

摘要

世界卫生组织（WHO）呼吁消除作为一个公共卫生问题的宫颈癌。通过人乳头瘤病毒（HPV）检测进行宫颈癌筛查是消除战略的核心组成部分，设定的目标是让70%的女性在一生中接受两次筛查。在本综述中，我们讨论了在全球范围内增加HPV筛查的技术障碍和机遇。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/186a/10431663/8b9c78311e8a/pgph.0001982.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/186a/10431663/f2d941114ef1/pgph.0001982.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/186a/10431663/8b9c78311e8a/pgph.0001982.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/186a/10431663/f2d941114ef1/pgph.0001982.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/186a/10431663/8b9c78311e8a/pgph.0001982.g002.jpg

相似文献

1
Toward 70% cervical cancer screening coverage: Technical challenges and opportunities to increase access to human papillomavirus (HPV) testing.迈向70%的宫颈癌筛查覆盖率：增加人乳头瘤病毒（HPV）检测可及性的技术挑战与机遇
PLOS Glob Public Health. 2023 Aug 16;3(8):e0001982. doi: 10.1371/journal.pgph.0001982. eCollection 2023.
2
Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.在 181 个国家/地区扩大人乳头瘤病毒疫苗接种和宫颈癌筛查的影响，以及在 2020-99 年全球消除宫颈癌的可能性：一项建模研究。
Lancet Oncol. 2019 Mar;20(3):394-407. doi: 10.1016/S1470-2045(18)30836-2. Epub 2019 Feb 19.
3
Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries.实现世界卫生组织宫颈癌消除目标的死亡率影响：78 个低收入和中低收入国家的比较建模分析。
Lancet. 2020 Feb 22;395(10224):591-603. doi: 10.1016/S0140-6736(20)30157-4. Epub 2020 Jan 30.
4
Integrating human papillomavirus testing as a point-of care service using GeneXpert platforms: Findings and lessons from a Kenyan pilot study (2019-2020).整合人乳头瘤病毒检测作为使用 GeneXpert 平台的即时护理服务：肯尼亚试点研究的发现和经验教训（2019-2020 年）。
PLoS One. 2023 May 25;18(5):e0286202. doi: 10.1371/journal.pone.0286202. eCollection 2023.
5
Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.HPV 疫苗接种和宫颈筛查对宫颈癌消除的影响：78 个低收入和中低收入国家的比较建模分析。
Lancet. 2020 Feb 22;395(10224):575-590. doi: 10.1016/S0140-6736(20)30068-4. Epub 2020 Jan 30.
6
Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic HIV infection and active HIV control.坦桑尼亚消除宫颈癌：在地方性 HIV 感染和积极控制 HIV 的背景下消除宫颈癌的建模分析。
Int J Cancer. 2021 Jul 15;149(2):297-306. doi: 10.1002/ijc.33533. Epub 2021 Mar 24.
7
Integrated cervical cancer screening in Mayuge District Uganda (ASPIRE Mayuge): a pragmatic sequential cluster randomized trial protocol.乌干达马尤盖区综合宫颈癌筛查（ASPIRE 马尤盖）：一项实用的序贯集群随机试验方案。
BMC Public Health. 2020 Jan 31;20(1):142. doi: 10.1186/s12889-020-8216-9.
8
The road to cervical cancer elimination in Malaysia: Evaluation of the impact and cost-effectiveness of human papillomavirus screening with self-collection and digital registry support.马来西亚消除宫颈癌的道路：评估自我采集和数字登记支持的人乳头瘤病毒筛查的影响和成本效益。
Int J Cancer. 2021 Dec 15;149(12):1997-2009. doi: 10.1002/ijc.33759. Epub 2021 Aug 25.
9
Optimizing high risk HPV-based primary screening for cervical cancer in low- and middle-income countries: opportunities and challenges.优化低收入和中等收入国家基于高危型人乳头瘤病毒的宫颈癌初筛：机遇与挑战
Minerva Ginecol. 2019 Oct;71(5):365-371. doi: 10.23736/S0026-4784.19.04468-X.
10
Towards elimination of cervical cancer - human papillomavirus (HPV) vaccination and cervical cancer screening in Asian National Cancer Centers Alliance (ANCCA) member countries.迈向消除宫颈癌——亚洲国家癌症中心联盟（ANCCA）成员国的人乳头瘤病毒（HPV）疫苗接种与宫颈癌筛查
Lancet Reg Health West Pac. 2023 Aug 1;39:100860. doi: 10.1016/j.lanwpc.2023.100860. eCollection 2023 Oct.

引用本文的文献

1
High-risk human papillomavirus testing for underscreened populations: cost-effectiveness and affordability in three country settings.对筛查不足人群进行高危型人乳头瘤病毒检测：三个国家背景下的成本效益与可负担性
BMC Public Health. 2025 Jul 29;25(1):2570. doi: 10.1186/s12889-025-23791-0.
2
Advancing Cervical Cancer Prevention Equity: Innovations in Self-Sampling and Digital Health Technologies Across Healthcare Settings.推进宫颈癌预防公平性：跨医疗保健环境的自我采样和数字健康技术创新
Diagnostics (Basel). 2025 May 6;15(9):1176. doi: 10.3390/diagnostics15091176.
3
Targeting ferroptosis for precision medicine in cervical cancer.

本文引用的文献

1
The Implementation of a Primary HPV Self-Testing Cervical Screening Program in Malaysia through Program ROSE-Lessons Learnt and Moving Forward.马来西亚通过 ROSE 计划实施 HPV 自我检测宫颈癌筛查项目：经验与展望
Curr Oncol. 2022 Oct 2;29(10):7379-7387. doi: 10.3390/curroncol29100579.
2
Engineering a sustainable future for point-of-care diagnostics and single-use microfluidic devices.为即时诊断和一次性微流控器件打造可持续的未来。
Lab Chip. 2022 Aug 23;22(17):3122-3137. doi: 10.1039/d2lc00380e.
3
Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis.
靶向铁死亡用于宫颈癌的精准医学
Apoptosis. 2025 May 7. doi: 10.1007/s10495-025-02120-1.
4
Comparing visual inspection with acetic acid, with and without Lugol's Iodine for triage of HPV self-sample positive women in Ethiopia: a randomized controlled trial.比较醋酸、卢戈氏碘液染色肉眼观察法以及二者联合用于埃塞俄比亚 HPV 自我采样阳性女性患者初筛的效果：一项随机对照试验
Int J Gynecol Cancer. 2024 Nov 4;34(11):1691-1697. doi: 10.1136/ijgc-2024-005694.
5
Looking Back, Moving Forward: Challenges and Opportunities for Global Cervical Cancer Prevention and Control.回顾过去，展望未来：全球宫颈癌预防与控制的挑战与机遇。
Viruses. 2024 Aug 25;16(9):1357. doi: 10.3390/v16091357.
6
Triage Strategies for Non-16/Non-18 HPV-Positive Women in Primary HPV-Based Cervical Cancer Screening: p16/Ki67 Dual Stain vs. Cytology.基于人乳头瘤病毒（HPV）的原发性宫颈癌筛查中16/18型HPV阴性女性的分流策略：p16/Ki67双重染色与细胞学检查的比较
Cancers (Basel). 2023 Oct 21;15(20):5095. doi: 10.3390/cancers15205095.
全球 202 个国家和地区的宫颈癌筛查规划和年龄别覆盖估计：综述和综合分析。
Lancet Glob Health. 2022 Aug;10(8):e1115-e1127. doi: 10.1016/S2214-109X(22)00241-8.
4
HPV testing of self-samples: Influence of collection and sample handling procedures on clinical accuracy to detect cervical precancer.自我采集样本的HPV检测：采集和样本处理程序对检测宫颈上皮内瘤变临床准确性的影响。
Lancet Reg Health Eur. 2022 Feb 17;14:100332. doi: 10.1016/j.lanepe.2022.100332. eCollection 2022 Mar.
5
Clinical Utility of Reflex Testing with Cancer Biomarkers to Improve Diagnostic Accuracy of Primary Human Papillomavirus Screening.利用癌症生物标志物进行反射测试以提高原发性人乳头瘤病毒筛查的诊断准确性的临床实用性。
Cancer Epidemiol Biomarkers Prev. 2022 Mar 1;31(3):595-603. doi: 10.1158/1055-9965.EPI-21-0972.
6
Hands-On Training Courses for Cervical Cancer Screening, Diagnosis, and Treatment Procedures in Low- and Middle-Income Countries.面向中低收入国家的宫颈癌筛查、诊断和治疗操作的实践培训课程。
JCO Glob Oncol. 2022 Jan;8:e2100214. doi: 10.1200/GO.21.00214.
7
Clinical performance of high-risk HPV testing on self-samples versus clinician samples in routine primary HPV screening in the Netherlands: An observational study.荷兰常规初级HPV筛查中高危型HPV自我采样与临床医生采样的临床性能：一项观察性研究。
Lancet Reg Health Eur. 2021 Nov 9;11:100235. doi: 10.1016/j.lanepe.2021.100235. eCollection 2021 Dec.
8
Worldwide use of HPV self-sampling for cervical cancer screening.全球范围内使用 HPV 自我采样进行宫颈癌筛查。
Prev Med. 2022 Jan;154:106900. doi: 10.1016/j.ypmed.2021.106900. Epub 2021 Nov 30.
9
The development of "automated visual evaluation" for cervical cancer screening: The promise and challenges in adapting deep-learning for clinical testing: Interdisciplinary principles of automated visual evaluation in cervical screening.用于宫颈癌筛查的“自动化视觉评估”的发展：将深度学习应用于临床检测的前景与挑战：宫颈癌筛查中自动化视觉评估的跨学科原则。
Int J Cancer. 2022 Mar 1;150(5):741-752. doi: 10.1002/ijc.33879. Epub 2021 Dec 6.
10
Accuracy of human papillomavirus tests on self-collected urine versus clinician-collected samples for the detection of cervical precancer: a systematic review and meta-analysis.人乳头瘤病毒检测在自行采集尿液与临床医生采集样本检测宫颈癌前病变的准确性：系统评价和荟萃分析。
J Gynecol Oncol. 2022 Jan;33(1):e4. doi: 10.3802/jgo.2022.33.e4. Epub 2021 Oct 7.